Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages.
Endocrinology. 2020 May 30;bqaa086.
RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice
Gefitinib purchased from AbMole
Clin Cancer Res. 2018 Nov 15;24(22):5658-5672.
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target.
Gefitinib purchased from AbMole
Clin Cancer Res. 2018 Jan 1;24(1):197-208.
Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM
Gefitinib purchased from AbMole
Sci Rep. 2017 May 8;7(1):1578.
Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wallmediated lipolysis, inflammation and dysglycemia
Gefitinib purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | MDA-361, SKBR-3, MDA-453 and BT-474 cells |
Preparation method | Monolayer Growth and Anchorage-independent Growth Assays. For monolayer growth, cells were seeded at a density of 3–4 104 cells in 12-well plates. Twenty-four h later, ZD1839 was added to the cells. Fresh medium ZD1839 was replaced on day 3. On day 5, cells were harvested by trypsinization and counted with a Zeiss Coulter Counter (Beckman Coulter, Miami, FL). Colony-forming assays in soft agarose were performed as described previously (30). Tumor cell colonies measuring 50 m were counted after 7 days using an Omnicon 3800 colony counter and Tumor Colony Analysis V2.IIA software (Imaging Products International, Inc.). |
Concentrations | 0.1–10 µ M |
Incubation time | 4 days |
Animal Experiment | |
---|---|
Animal models | BT-474 cells Xenograft in Athymic Mice |
Formulation | 0.05% Tween 80 |
Dosages | 200 mg/kg/day for 28 days |
Administration | oral gavage |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Molecular Weight | 446.90 |
Formula | C22H24ClFN4O3 |
CAS Number | 184475-35-2 |
Purity | 99.97% |
Solubility | DMSO 68 mg/mL |
Storage | at -20°C |
Related EGFR/HER2 Products |
---|
BLU-945
Blu-945 is a potent inhibitor of selective epidermal growth factor receptor (EGFR). |
Sunvozertinib
Sunvozertinib (DZD9008) is an effective inhibitor of ErbBs (EGFR, Her2, especially mutants) and BTK. |
(S)-Sunvozertinib
(S)-Sunvozertinib ((S)-DZD9008) is the S-enantiomer of Sunvozertinib, EGFR exon 20 NPH and ASV insertion, EGFR L858R/T790M mutation and Her2 exon 20 YVMA insertion (IC50 was 51.2 nM, 51.9 nM, 1 nM and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK. |
(Rac)-JBJ-04-125-02
(Rac)-JBJ-04-125-02 is a racemate of JBJ-04-125-02, which is a potent, selectively mutated, allosteric and oral active EGFR inhibitor. The IC50 of EGFRL858R/T790M was 0.26 nM. |
AZ7550 Mesylate
AZ7550 Mesylate is an active metabolite of AZD9291, AZ7550 inhibits IGF1R activity,IC50 1.6 μM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.